Placebo-PreNCT06831656
TetraSOD® Supplementation and Exercise Performance
A study testing Tetraselmis chuii-Pre and Tetraselmis chuii-Post in people with Placebo-Pre and Placebo-Post, run by Loughborough University at 1 site in United Kingdom.
Trial summary
Tetraselmis chuii (TetraSOD) is a marine microalgae that has been reported to improve antioxidant responses in human skeletal muscle cells treated with TetraSOD and to improve recovery from muscle damaging exercise in humans supplemented with TetraSOD. Read more about this study
- Who is it for?
- Ages 18 to 40 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Placebo-Pre, Placebo-Post, Tetraselmis Chuii-Pre
- What is being tested?
- Tetraselmis chuii-Pre and Tetraselmis chuii-Post
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 15 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 4 Oct 2019to 19 May 2021
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 40 years
- Men only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Healthy male (as determined by the Health Screening Questionnaire)
- Adult (aged ≥18 and ≤40 years old)
- Recreationally-active (≥2 and ≤4 exercise sessions per week) and a V̇O2max of ≥ 35 mL/kg/min and ≤ 65 mL/kg/min as determined from the preliminary exercise test
- No known history of gastric, digestive, cardiovascular, renal disease or any other orthopaedic diseases related to motor organs
- Non-smoker
- Healthy body mass index (BMI; ≥18.5 and ≤24.9 kg/m2)
Show all 10Show fewer
- Not using any dietary supplements, including antioxidant and nitrate-rich supplements, currently or in the past one month
- Not a heavy drinker (≤ 14 units of alcohol) on most weeks
- Not using medication that may affect study measures
- Not participating in other studies currently or in the past two months prior to the consenting session (visit 1) or having an intention to participate in other studies over the period of this study
Who cannot join
- Female
- Aged <18 and >40 years old
- Sedentary or highly trained with a respective V̇O2max of < 35 mL/kg/min and > 65 mL/kg/min as determined from the preliminary exercise test
- History of gastric, digestive, cardiovascular, renal disease or any other orthopaedic diseases related to motor organs
- Smoker
- Unhealthy body mass index (BMI;<18.5 and >24.9 kg/m2)
Show all 10Show fewer
- Using any dietary supplements, including antioxidant and nitrate-rich supplements, currently or in the past one month
- Heavy drinker (> 14 units of alcohol) on most weeks
- Using medication that may affect study measures
- Participating in other studies currently or in the past two months prior to the consenting session (visit 1) or having an intention to participate in other studies over the period of this study
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site
Loughborough University
Loughborough, Leicestershire, LE7 7WG
About this study
Official title: The Effect of TetraSOD® Supplementation on Blood Oxidative Stress Biomarkers and Endurance Exercise Performance in Healthy Adults
Tetraselmis chuii (TetraSOD) is a marine microalgae that has been reported to improve antioxidant responses in human skeletal muscle cells treated with TetraSOD and to improve recovery from muscle damaging exercise in humans supplemented with TetraSOD. However, the effects of TetraSOD supplementation on endurance performance and physiology is less clear. This study assessed the effect of short-term TetraSOD supplementation on endurance performance and physiology in healthy adults.
Read the detailed description
It is well documented that the production of reactive oxygen species (ROS; unstable molecules that react easily with and damage other molecules in a cell) increases in-line with the intensity and duration of exercise . Although increased ROS production during exercise is initially managed by a variety of 'antioxidants', continued ROS production exceeds the capacity of this antioxidant defense system leading to the development of oxidative stress and impaired exercise performance. Therefore, interventions that can lessen exercise-induced oxidative stress have the potential to improve exercise performance. While dietary supplementation with antioxidant vitamins (e.g. vitamin C and E) has this potential, such interventions do not typically improve exercise performance.
Therefore, further research is required to investigate the potential for novel nutritional supplements to lessen exercise-induced oxidative stress and to improve exercise performance.
Tetraselmis chuii (TetraSOD) is a natural marine microalgae product. Recent preliminary evidence suggests that treating human skeletal muscle cells with TetraSOD can increase the production of antioxidant enzymes to limit oxidative stress development. In addition, TetraSOD supplementation has been reported to improve recovery from muscle damaging exercise. However, the effects of TetraSOD supplementation on endurance performance and physiology is less clear.
The purpose of this study was to assess the effect of short-term TetraSOD supplementation on endurance performance and physiology in healthy adults.
- Being tested
- Placebo-Pre, Placebo-Post, Tetraselmis chuii-Pre, Tetraselmis chuii-Post
- Keywords
- Microalgae, Endurance performance
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Placebo-PreOther
No dietary supplementation prior to undergoing the placebo supplement
Placebo-PostDietary supplement
14 days of supplementation with 25 mg/day hemicellulose crystalline
Tetraselmis chuii-PreOther
No dietary supplementation prior to undergoing the tetraselmis chuii supplement
Tetraselmis chuii-PostDietary supplement
14 days of supplementation with 25 mg/day tetraselmis chuii
| Study group | Role | What they receive |
|---|---|---|
| Placebo-Pre | Other | No supplementation prior to undergoing the placebo supplement Receives: Other: Placebo-Pre |
| Placebo-post | Placebo comparator | Placebo supplementation Receives: Dietary Supplement: Placebo-Post |
| Tetraselmis chuii-Pre | Other | No supplementation prior to undergoing the Tetraselmis chuii supplement Receives: Other: Tetraselmis chuii-Pre |
| Tetraselmis chuii-Post | Active comparator | Tetraselmis chuii supplementation Receives: Dietary Supplement: Tetraselmis chuii-Post |
What is being measured
The primary outcome is the main question the study is designed to answer.
Time to exhaustion during a severe-intensity cycle ergometry test continued until exhaustion
Time to exhaustion during severe-intensity cycle ergometry measured in seconds
Measured: One assessment prior to and 14 days following the placebo supplementation, and one assessment prior to and 14 days following Tetraselmis chuii supplementation
End-exercise pulmonary oxygen uptake during a severe-intensity cycle ergometry test continued until exhaustion measured using an online gas analyser
Pulmonary oxygen uptake at the end of a severe-intensity cycling bout completed until exhaustion to provide an estimate of VO2max measured in L/min using a breath-by-breath gas exchange analyzer and taken as the mean over the final 30 s of the test.
Measured: One assessment prior to and 14 days following the placebo supplementation, and one assessment prior to and 14 days following Tetraselmis chuii supplementation
Secondary outcomes (2)
End-exercise blood lactate concentration during a severe-intensity cycle ergometry test continued until exhaustion
Blood lactate concentration at the end of a severe-intensity cycling bout continued until exhaustion measured in mmol/L using an autoanalyzer
Measured: One assessment prior to and 14 days following the placebo supplementation, and one assessment prior to and 14 days following Tetraselmis chuii supplementation
End-exercise rating of perceived exertion using the Borg 6-20 scale during a severe-intensity cycle ergometry test continued until exhaustion
Assessment of rating of perceived exertion at the end of a severe-intensity cycling bout completed until exhaustion using the Borg 6-20 scale where 6 = no exercise and 20 = maximal exertion with measurement units of arbitrary units.
Measured: One assessment prior to and 14 days following the placebo supplementation, and one assessment prior to and 14 days following Tetraselmis chuii supplementation
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Feb 2025
- Study start4 Oct 2019
- Primary completion19 May 2021
- Study completion19 May 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Placebo-PreStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- Crossover Assignment 13 participants completed 2 experimental conditions in a randomized order.
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 15 participants (actual)
Sponsor and investigators
- Lead sponsor
- Loughborough University
- Sponsor type
- University, hospital or other
- Collaborators
- Fitoplancton Marino, S.L.
- Responsible party
- Principal investigator, Stephen Bailey, Loughborough University
- Investigators
- Stephen J Bailey, Principal investigator, Loughborough University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06831656
- Sponsor's protocol ID
- R19-P160
- Status last verified
- Dec 2024
- First submitted
- 31 Dec 2024
- Last updated
- 18 Feb 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Feb 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of TetraSOD® Supplementation on Blood Oxidative Stress Biomarkers and Endurance Exercise Performance in Healthy Adults
- ClinicalTrials.gov ID
- NCT06831656
- Acronym / sponsor ID
- R19-P160
- Keywords
- Microalgae, Endurance performance
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 15 participants (actual)
- Lead sponsor
- Loughborough UniversityUniversity, hospital or other
- Collaborators
- Fitoplancton Marino, S.L.
- Study start
- 4 Oct 2019 (actual)
- Primary completion
- 19 May 2021 (actual)
- Study completion
- 19 May 2021 (actual)
- First posted
- 18 Feb 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Tetraselmis chuii (TetraSOD) is a marine microalgae that has been reported to improve antioxidant responses in human skeletal muscle cells treated with TetraSOD and to improve recovery from muscle damaging exercise in humans supplemented with TetraSOD. However, the effects of TetraSOD supplementation on endurance performance and physiology is less clear. This study assessed the effect of short-term TetraSOD supplementation on endurance performance and physiology in healthy adults.
Detailed description
It is well documented that the production of reactive oxygen species (ROS; unstable molecules that react easily with and damage other molecules in a cell) increases in-line with the intensity and duration of exercise . Although increased ROS production during exercise is initially managed by a variety of 'antioxidants', continued ROS production exceeds the capacity of this antioxidant defense system leading to the development of oxidative stress and impaired exercise performance. Therefore, interventions that can lessen exercise-induced oxidative stress have the potential to improve exercise performance. While dietary supplementation with antioxidant vitamins (e.g. vitamin C and E) has this potential, such interventions do not typically improve exercise performance.
Therefore, further research is required to investigate the potential for novel nutritional supplements to lessen exercise-induced oxidative stress and to improve exercise performance.
Tetraselmis chuii (TetraSOD) is a natural marine microalgae product. Recent preliminary evidence suggests that treating human skeletal muscle cells with TetraSOD can increase the production of antioxidant enzymes to limit oxidative stress development. In addition, TetraSOD supplementation has been reported to improve recovery from muscle damaging exercise. However, the effects of TetraSOD supplementation on endurance performance and physiology is less clear.
The purpose of this study was to assess the effect of short-term TetraSOD supplementation on endurance performance and physiology in healthy adults.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind (participant, investigator)
- Number of arms
- 4
- Model description
- Crossover Assignment 13 participants completed 2 experimental conditions in a randomized order.
| Arm | Type | Receives |
|---|---|---|
| Placebo-Pre | Other | Other: Placebo-PreNo supplementation prior to undergoing the placebo supplement |
| Placebo-post | Placebo comparator | Dietary Supplement: Placebo-PostPlacebo supplementation |
| Tetraselmis chuii-Pre | Other | Other: Tetraselmis chuii-PreNo supplementation prior to undergoing the Tetraselmis chuii supplement |
| Tetraselmis chuii-Post | Active comparator | Dietary Supplement: Tetraselmis chuii-PostTetraselmis chuii supplementation |
Who may qualify
- Ages
- 18 to 40 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (10 listed)
- Healthy male (as determined by the Health Screening Questionnaire)
- Adult (aged ≥18 and ≤40 years old)
- Recreationally-active (≥2 and ≤4 exercise sessions per week) and a V̇O2max of ≥ 35 mL/kg/min and ≤ 65 mL/kg/min as determined from the preliminary exercise test
- No known history of gastric, digestive, cardiovascular, renal disease or any other orthopaedic diseases related to motor organs
- Non-smoker
Key exclusion criteria (10 listed)
- Female
- Aged <18 and >40 years old
- Sedentary or highly trained with a respective V̇O2max of < 35 mL/kg/min and > 65 mL/kg/min as determined from the preliminary exercise test
- History of gastric, digestive, cardiovascular, renal disease or any other orthopaedic diseases related to motor organs
- Smoker
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Placebo-PreNo dietary supplementation prior to undergoing the placebo supplement | Other | Placebo-Pre |
| Placebo-Post14 days of supplementation with 25 mg/day hemicellulose crystalline | Dietary supplement | Placebo-post |
| Tetraselmis chuii-PreNo dietary supplementation prior to undergoing the tetraselmis chuii supplement | Other | Tetraselmis chuii-Pre |
| Tetraselmis chuii-Post14 days of supplementation with 25 mg/day tetraselmis chuii | Dietary supplement | Tetraselmis chuii-Post |
Primary outcome
Time to exhaustion during a severe-intensity cycle ergometry test continued until exhaustion
Time frame: One assessment prior to and 14 days following the placebo supplementation, and one assessment prior to and 14 days following Tetraselmis chuii supplementation
Time to exhaustion during severe-intensity cycle ergometry measured in seconds
End-exercise pulmonary oxygen uptake during a severe-intensity cycle ergometry test continued until exhaustion measured using an online gas analyser
Time frame: One assessment prior to and 14 days following the placebo supplementation, and one assessment prior to and 14 days following Tetraselmis chuii supplementation
Pulmonary oxygen uptake at the end of a severe-intensity cycling bout completed until exhaustion to provide an estimate of VO2max measured in L/min using a breath-by-breath gas exchange analyzer and taken as the mean over the final 30 s of the test.
2 secondary outcomes
End-exercise blood lactate concentration during a severe-intensity cycle ergometry test continued until exhaustion
Time frame: One assessment prior to and 14 days following the placebo supplementation, and one assessment prior to and 14 days following Tetraselmis chuii supplementation
End-exercise rating of perceived exertion using the Borg 6-20 scale during a severe-intensity cycle ergometry test continued until exhaustion
Time frame: One assessment prior to and 14 days following the placebo supplementation, and one assessment prior to and 14 days following Tetraselmis chuii supplementation
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Feb 2025.
Related trials for Placebo-Pre
RecruitingPhase 4
Efficacy and Safety of a Half-dose Bolus of r-SAK Prior to Primary PCI in ST-elevation Myocardial Infarction
ST Elevation Myocardial Infarction
RecruitingPhase 1/2
HS235 Study in Overweight and Obese Participants With Combined Pre and Post-Capillary Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction
Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
RecruitingPhase 3
Ferric Derisomaltose and Outcomes in the Recovery of Gynecologic Oncology: ERAS (Enhanced Recovery After Surgery)
Gynecologic Cancer, Anemia
Not yet recruitingPhase 2
Efficacy and Safety of OsrhCT Before Upper Endoscopy on Improving Visualization of the Gastric Mucosa.
Gastric Mucosal Lesion
Active, not recruitingPhase 3
Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
Functioning Pancreatic Neuroendocrine Tumor, Intermediate Grade Lung Neuroendocrine Neoplasm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Stephen J Bailey principal investigator
Loughborough University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Tetraselmis chuii-Pre and Tetraselmis chuii-Post in people with Placebo-Pre and Placebo-Post, run by Loughborough University at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Feb 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Time to exhaustion during a severe-intensity cycle ergometry test continued until exhaustion (time frame: One assessment prior to and 14 days following the placebo supplementation, and one assessment prior to and 14 days following Tetraselmis chuii supplementation). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Feb 2025.